OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO exercised or converted 5,426 RGEN derivative securities | OQRO

Home
Insider trades
Repligen
CEO exercised or converted 5,426 RGEN derivative securities

Insider trades

Insider trade

CEO exercised or converted 5,426 RGEN derivative securities

Traded Sep 21, 2026 · Filed Sep 23, 2026

RGERepligenRGEN

5,426
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 21, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 23, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001628280-26-063026

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Sep 23, 2026, 12:07 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

REPLIGEN CORP

Issuer CIK

730272

Ticker

RGEN

Reporting person

Olivier Loeillot

Relationship

Director, Officer

Officer title

Chief Executive Officer

Security

Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Sep 21, 2026

Transaction code

Shares / units

5,426

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

5,426

Ownership form

Direct

Amendment

Footnotes from the filing

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

Around the same time

Olivier Loeillot (Chief Executive Officer) sold ~$238K of Repligen

Scheduled in advanceFiled yesterday

Olivier LoeillotChief Executive Officer

Filed yesterday

4,202Shares · @ $154.96

Traded Oct 5 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Olivier Loeillot (Chief Executive Officer) sold ~$798K of Repligen

Scheduled in advanceFiled yesterday